Biogen Inc. (BIIB)
Health Care7 articles
Price chart
Biogen Inc. (BIIB) overview
Biogen is a biotech focused on neurological diseases. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Biogen Inc. trades on the NasdaqGS under the ticker symbol BIIB. As of the most recent market data, the stock was priced around $205.99, down 1.40% on the session, giving Biogen Inc. a market capitalization of roughly $30.41B.
Over the past 52 weeks, BIIB has traded between $121.05 and $219.72. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 22.1, a common gauge of how richly the market prices the company's earnings.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch BIIB
As one of the larger companies in the Health Care sector, Biogen Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch BIIB for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest BIIB news
Biogen Stock Surges Today Amid Market Interest and Activity
Biogen's stock is experiencing a rally today, though specific figures related to the price movement are not disclosed. The increase follows heightened market interest, but the article does not provide details about trading volumes or percentage changes. There are no concrete data points to indicate why this rally is occurring or its implications for investors. Market participants should monitor Biogen (BIIB) developments, as the lack of detailed data leaves uncertainty regarding this movement's sustainability.
Read More: Biogen Stock Surges Today Amid Market Interest and Activity
Biogen (BIIB) Buy Rating Reiterated After RayThera Acquisition
Needham has reiterated a Buy rating on Biogen (BIIB) following its acquisition of RayThera. This acquisition aligns with Biogen's strategic focus on expanding its offerings in neurodegenerative diseases. Needham has highlighted the potential for increased market share and revenue growth post-acquisition. Such strategic moves may positively influence investor confidence and stock performance for Biogen.
Read More: Biogen (BIIB) Buy Rating Reiterated After RayThera Acquisition
Biogen (BIIB) Stock Upgrade Due to Pipeline Outlook
Needham has upgraded Biogen (BIIB) due to optimism surrounding its pipeline. While specific figures related to the target price or P/E ratios were not disclosed, upgrades can indicate potential growth in stock value and investor confidence. This action is significant as it may lead to increased trading volume and interest in Biogen shares. Market responses to upgrades often correlate positively with future price movements.
Read More: Biogen (BIIB) Stock Upgrade Due to Pipeline Outlook
Biogen (BIIB) Shares Fall 6% After Alzheimer’s Drug Trial Results
Biogen (BIIB) shares dropped 6% following the announcement of positive data from an Alzheimer's drug trial. The trial outcomes, while favorable, did not meet market expectations for immediate approval or broader commercial viability. This decline reflects investor skepticism regarding the drug's potential impact on revenue growth and market positioning. The market will be watching closely for further developments that could influence Biogen's stock performance.
Read More: Biogen (BIIB) Shares Fall 6% After Alzheimer’s Drug Trial Results
Premarket Stocks: Versant, Biogen, Cisco Moves and Impacts
Premarket trading saw significant movements in stocks such as Versant, Biogen, and Cisco. The specifics of the price changes or trading volumes were not indicated in the article. These price movements often reflect investor sentiment and can lead to changes in market valuations. Monitoring these stocks can provide insights into broader market trends, especially around earnings reports or other significant corporate announcements.
Read More: Premarket Stocks: Versant, Biogen, Cisco Moves and Impacts
Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS
UBS has upgraded Biogen (BIIB) stock, citing favorable pipeline catalysts as a key reason. The target price for Biogen shares has been raised to $225. This adjustment reflects confidence in the company's growth potential and anticipated drug approvals. The upgrade may positively influence market perception and investor interest in Biogen moving forward.
Read More: Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS
Biogen (BIIB) to Acquire Apellis for $5.6 Billion
Biogen (BIIB) announced plans to acquire Apellis Pharmaceuticals for $5.6 billion. This acquisition aims to enhance Biogen's portfolio in the neurological disorders market. The transaction is expected to be finalized in the second half of 2024, pending regulatory approvals. This move may increase Biogen's market presence and influence, reflecting its strategy to diversify and grow its offerings post patent expirations of major products.
Read More: Biogen (BIIB) to Acquire Apellis for $5.6 BillionMore Health Care stocks
Frequently asked questions
Is Biogen Inc. in the S&P 500?
Yes. Biogen Inc. (BIIB) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is BIIB in?
Biogen Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest BIIB news?
This page collects recent Biogen Inc. (BIIB) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Biogen Inc.'s stock price?
As of the most recent market data, Biogen Inc. (BIIB) traded at approximately $205.99. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Biogen Inc.'s market cap?
Biogen Inc. has a market capitalization of roughly $30.41B, based on its most recent share price and shares outstanding.
What is BIIB's P/E ratio?
BIIB trades at a trailing price-to-earnings ratio of about 22.1. The P/E ratio compares a company's share price to its earnings per share.